Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients

• Príomhchruthaitheoirí: Beatriz Colom-Fernández (Údar), Anna Kreutzman (Údar), Ana Marcos-Jiménez (Údar), Valentín García-Gutiérrez (Údar), Carlos Cuesta-Mateos (Údar), Itxaso Portero-Sainz (Údar), Yaiza Pérez-García (Údar), Luis Felipe Casado (Údar), Fermín Sánchez-Guijo (Údar), Joaquín Martínez-López (Údar), Rosa M. Ayala (Údar), Concha Boqué (Údar), Blanca Xicoy (Údar), Isabel Montero (Údar), César Soto (Údar), Raquel Paz (Údar), Gabriela Silva (Údar), Lorena Vega-Piris (Údar), Juan Luis Steegmann (Údar), Cecilia Muñoz-Calleja (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2019-11-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. Since the underly...